HRP20231093T1 - Dulaglutid, namijenjen liječenju kronične bolesti bubrega - Google Patents
Dulaglutid, namijenjen liječenju kronične bolesti bubrega Download PDFInfo
- Publication number
- HRP20231093T1 HRP20231093T1 HRP20231093TT HRP20231093T HRP20231093T1 HR P20231093 T1 HRP20231093 T1 HR P20231093T1 HR P20231093T T HRP20231093T T HR P20231093TT HR P20231093 T HRP20231093 T HR P20231093T HR P20231093 T1 HRP20231093 T1 HR P20231093T1
- Authority
- HR
- Croatia
- Prior art keywords
- dulaglutide
- patient
- intended
- treatment
- kidney disease
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title claims 9
- 108010005794 dulaglutide Proteins 0.000 title claims 9
- 208000020832 chronic kidney disease Diseases 0.000 title claims 5
- 206010062237 Renal impairment Diseases 0.000 claims 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 229960003624 creatine Drugs 0.000 claims 1
- 239000006046 creatine Substances 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (6)
1. Dulaglutid, namijenjen upotrebi u liječenju kronične bolesti bubrega (CKD) kod pacijenta, gdje pacijent ima:
a) procijenjenu brzinu glomerulararne filtracije (eGFR) između 15-89 ml/min/1,73 m2; i
b) omjer između albumina u mokraći (mg/dl) i kreatina u mokraći (g/dl) (UACR) veći od 300 mg/g; naznačen time što se djelotvornu količinu dulaglutida primijenjuje jednom tjedno u trajanju od najmanje 6 mjeseci; i što se dulaglutid primijenjuje u dozi od 1,5 mg.
2. Dulaglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što CKD kod pacijenta nije posljedica dijabetesa melitusa tipa 2.
3. Dulaglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je CKD kod pacijenta posljedica dijabetesa melitusa tipa 2.
4. Dulaglutid, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pacijent ima eGFR povezan s oštećenjem bubrega između 60-89 ml/min/1,73 m2.
5. Dulaglutid, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što pacijent ima eGFR povezan s oštećenjem bubrega između 60-75 ml/min/1,73 m2.
6. Dulaglutid, namijenjen upotrebi u skladu s patentnim zahtjevom 4 ili patentnim zahtjevom 5, naznačen time što se navedenu primjenu nastavlja u trajanju od najmanje 1 godinu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513556P | 2017-06-01 | 2017-06-01 | |
| PCT/US2018/034278 WO2018222472A1 (en) | 2017-06-01 | 2018-05-24 | Dulaglutide for the treatment of chronic kidney disease |
| EP18730908.3A EP3630164B1 (en) | 2017-06-01 | 2018-05-24 | Dulaglutide for the treatment of chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231093T1 true HRP20231093T1 (hr) | 2023-12-22 |
Family
ID=62598054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231093TT HRP20231093T1 (hr) | 2017-06-01 | 2018-05-24 | Dulaglutid, namijenjen liječenju kronične bolesti bubrega |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200171129A1 (hr) |
| EP (2) | EP3630164B1 (hr) |
| JP (2) | JP7191043B2 (hr) |
| CN (1) | CN110650747A (hr) |
| CA (1) | CA3065295C (hr) |
| DK (1) | DK3630164T3 (hr) |
| ES (1) | ES2963464T3 (hr) |
| FI (1) | FI3630164T3 (hr) |
| HR (1) | HRP20231093T1 (hr) |
| HU (1) | HUE063776T2 (hr) |
| LT (1) | LT3630164T (hr) |
| PL (1) | PL3630164T3 (hr) |
| PT (1) | PT3630164T (hr) |
| RS (1) | RS64666B1 (hr) |
| SI (1) | SI3630164T1 (hr) |
| WO (1) | WO2018222472A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7221956B2 (ja) | 2017-11-21 | 2023-02-14 | イーライ リリー アンド カンパニー | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| AU2008275180A1 (en) | 2007-07-10 | 2009-01-15 | Eli Lilly And Company | GLP-1-Fc fusion protein formulation |
| EP2566469B1 (en) * | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
| WO2014202780A1 (en) * | 2013-06-21 | 2014-12-24 | Novo Nordisk A/S | Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes |
-
2018
- 2018-05-24 CA CA3065295A patent/CA3065295C/en active Active
- 2018-05-24 HR HRP20231093TT patent/HRP20231093T1/hr unknown
- 2018-05-24 WO PCT/US2018/034278 patent/WO2018222472A1/en active Application Filing
- 2018-05-24 DK DK18730908.3T patent/DK3630164T3/da active
- 2018-05-24 CN CN201880033295.9A patent/CN110650747A/zh active Pending
- 2018-05-24 LT LTEPPCT/US2018/034278T patent/LT3630164T/lt unknown
- 2018-05-24 RS RS20230908A patent/RS64666B1/sr unknown
- 2018-05-24 EP EP18730908.3A patent/EP3630164B1/en active Active
- 2018-05-24 JP JP2019565364A patent/JP7191043B2/ja active Active
- 2018-05-24 PL PL18730908.3T patent/PL3630164T3/pl unknown
- 2018-05-24 SI SI201830979T patent/SI3630164T1/sl unknown
- 2018-05-24 ES ES18730908T patent/ES2963464T3/es active Active
- 2018-05-24 FI FIEP18730908.3T patent/FI3630164T3/fi active
- 2018-05-24 HU HUE18730908A patent/HUE063776T2/hu unknown
- 2018-05-24 PT PT187309083T patent/PT3630164T/pt unknown
- 2018-05-24 US US16/615,609 patent/US20200171129A1/en not_active Abandoned
- 2018-05-24 EP EP23188793.6A patent/EP4279925A3/en active Pending
-
2022
- 2022-09-27 JP JP2022153483A patent/JP2023002547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3630164T3 (pl) | 2024-01-29 |
| JP7191043B2 (ja) | 2022-12-16 |
| EP4279925A2 (en) | 2023-11-22 |
| US20200171129A1 (en) | 2020-06-04 |
| CN110650747A (zh) | 2020-01-03 |
| JP2023002547A (ja) | 2023-01-10 |
| PT3630164T (pt) | 2023-09-14 |
| JP2020521765A (ja) | 2020-07-27 |
| LT3630164T (lt) | 2023-10-25 |
| CA3065295A1 (en) | 2018-12-06 |
| CA3065295C (en) | 2023-08-29 |
| DK3630164T3 (da) | 2023-10-02 |
| HUE063776T2 (hu) | 2024-01-28 |
| WO2018222472A1 (en) | 2018-12-06 |
| EP3630164A1 (en) | 2020-04-08 |
| EP4279925A3 (en) | 2024-01-24 |
| FI3630164T3 (fi) | 2023-11-06 |
| SI3630164T1 (sl) | 2023-10-30 |
| EP3630164B1 (en) | 2023-08-23 |
| RS64666B1 (sr) | 2023-11-30 |
| ES2963464T3 (es) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231093T1 (hr) | Dulaglutid, namijenjen liječenju kronične bolesti bubrega | |
| JP2018172440A5 (hr) | ||
| JP2015535209A5 (hr) | ||
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| MY147391A (en) | Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds | |
| WO2015049588A3 (en) | Systems for moving and circulating fluid to treat alzheimer's disease | |
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| JP2017014206A5 (hr) | ||
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| JP2009541348A5 (hr) | ||
| HRP20121029T4 (hr) | Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2 | |
| CA2574450A1 (en) | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| JP2016087438A5 (ja) | フィードフォワード制御を用いた、体外血液治療時における柔軟なクエン酸抗凝血用のためのシステム | |
| HRP20110713T1 (hr) | Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830 | |
| HRP20161566T1 (hr) | Terapijski agensi za reguliranje serumskog fosfora | |
| HRP20231469T1 (hr) | Poboljšani protokol za liječenje lupus nefritisa | |
| JP2017508004A5 (hr) | ||
| JP2017508455A5 (hr) | ||
| JP2017529355A5 (hr) | ||
| JP2020040998A5 (hr) | ||
| JP2018523711A5 (hr) | ||
| RU2013155841A (ru) | Способ ранней диагностики хронической болезни почек | |
| Strugaru | Vitamin B12 deficiency: case report |